Autophagy Inhibitors Development Services for Bladder Cancer

Inquiry

The process of autophagy presents a promising avenue for targeting cancer cells, thereby opening up new possibilities in the field of potential therapeutic interventions, particularly in the multidisciplinary management of bladder cancer. Alfa Cytology delves into crucial cellular processes associated with cancer cell survival and therapy resistance, aiming to facilitate the discovery and optimization of novel autophagy inhibitors for bladder cancer therapy. This effort caters to a diverse range of research organizations and companies involved in therapeutic development.

Introduction to Autophagy Inhibitors

Autophagy plays a dual role in cancer, suppressing tumor initiation and aiding in tumor cell survival under stress. In bladder cancer (BC), autophagy helps maintain genomic integrity and prevent proliferation and inflammation during early stages. However, established tumors exploit autophagy to endure adverse conditions. Studies have shown that inhibiting key autophagy-related proteins like ATG7 can reduce bladder cancer invasiveness. The paradoxical nature of autophagy in cancer therapy makes it crucial to identify when and how to inhibit autophagy to enhance treatment efficacy.

Fig.1 Overview of TAMs for cancer treatment. (Konac, E., et al., 2021) Fig.1 Apoptosis-autophagy-tumor progression and recurrence triad and the dual role of autophagy for therapeutic purposes in cancer. (Konac, E., et al., 2021)

The development and application of autophagy inhibitors offer promising avenues for improving bladder cancer therapies.

Inhibitor	Mechanism of action	Treatments combined with inhibitor
Chloroquine	Lysosomal lumen alkalizer	Cisplatin, radiotherapy, lapatinib or gefitinib
3-Methyladenine	PI3K inhibitor	Cisplatin, Fangchinoline, lapatinib or gefitinib
Icaritin	Protein synthesis inhibitor	Epirubicin
Frondoside A	Protein synthesis inhibitor	Cisplatin and gemcitabine
shRNA	Knockdown of Beclin1 and ATG7/ATG12	Cisplatin
siRNA	Suppression of ATG12	Lapatinib or gefitinib

Our Services

With our extensive experience, specialized expertise, and dedicated team of professionals, Alfa Cytology aims to offer a comprehensive solution for the development of autophagy inhibitors and expedited translation of promising drug candidates.

Assay Development and High-Throughput Screening

Custom assay development and high-throughput screening to identify potent autophagy inhibitors.

Mechanistic Studies

Detailed studies to elucidate the mechanism of action of potential autophagy inhibitors.

Preclinical Efficacy and Safety Testing

Conducting in vitro and in vivo studies to evaluate the efficacy and safety of autophagy inhibitors in preclinical models of bladder cancer.

Custom assay development and high-throughput screening to identify potent autophagy inhibitors.

Contact Us

Choose Alfa Cytology's expertise in autophagy inhibitor development to enhance your bladder cancer research. Our dedicated team and advanced capabilities ensure tailored solutions to meet your specific needs. Contact us today to learn how we can support your autophagy inhibitor development projects and drive your research forward with precision and excellence.

Reference

Konac, E., Kurman, Y., & Baltaci, S. Contrast effects of autophagy in the treatment of bladder cancer. Experimental biology and medicine (Maywood, N.J.), 2021, 246(3), 354–367.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.